FDA Extends Use of Oxbryta to Children Starting at Age 4

FDA Extends Use of Oxbryta to Children Starting at Age 4

314746

FDA Extends Use of Oxbryta to Children Starting at Age 4

The U.S. Food and Drug Administration (FDA) has agreed to expand the use of Oxbryta (voxelotor) — the first approved therapy targeting the underlying cause of sickle cell disease (SCD) — to children as young as 4. The therapy previously was approved for SCD patients ages 12 and older. This extension was accompanied by the agency’s approval of a dispersible once-daily 300 mg tablet of Oxbryta, shown to result in similar blood-related benefits as those seen with…

You must be logged in to read/download the full post.